-
-
-
-
-
-
-
BioCryst raises ORLADEYO drug price by 9% starting January 2026
-
-
-
-
-
-
-
BioCryst Pharma (BCRX) PT Lowered to $25 at Citizens After Missing 3Q Sales Consensus
-
-
-
-
-
-
-
Oppenheimer Downgrades Astria Therapeutics (ATXS) to Perform
-
-
-
-
-
-
-
BioCryst Pharma (BCRX) Tops Q2 EPS by 14c ; Offers Guidance
-
-
-
-
-
-
-
BioCryst Pharma (BCRX) Highlights Real-world Data Showing ORLADEYO Consistently Reduces HAE Attacks Across All Ages
-
-
-
-
-
-
-
Citizens JMP Reiterates Market Outperform Rating on BioCryst Pharma (BCRX)
-
-
-
-
-
-
-
BioCryst Pharma (BCRX) Misses Q4 EPS by 6c; offers outlook
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

